We have launched a board of Reviewer Editors - click this link to apply.
Our hope is that will give public credit for the reviewing work many of you are doing already. If you have any questions before you apply, please get in touch.
Apply to our Board of Reviewer Editors
Call For Papers
Infections in Immunocompromised Hosts
This special issue of the Annals of Clinical Microbiology and Antimicrobials will focus on infections in immunocompromised populations, and we welcome submissions relating to clinical presentations, antimicrobial therapy, epidemiology, pathogen diagnostics and host immunology including host-pathogen interaction.
Guest Editor - Dr David Lowe (University College London)
Articles
-
-
Molecular characterization of methicillin-resistant Staphylococcus aureus among insulin-dependent diabetic individuals in Brazil
-
Evaluation of efflux pump activity and biofilm formation in multidrug resistant clinical isolates of Pseudomonas aeruginosa isolated from a Federal Medical Center in Nigeria
-
Role of Williamsia and Segniliparus in human infections with the approach taxonomy, cultivation, and identification methods
-
Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis
-
Identification of Staphylococcus aureus: DNase and Mannitol salt agar improve the efficiency of the tube coagulase test
-
Plasma CRP level is positively associated with the severity of COVID-19
-
Are we aware how contaminated our mobile phones with nosocomial pathogens?
The Erratum to this article has been published in Annals of Clinical Microbiology and Antimicrobials 2009 8:31
-
Treatment of Klebsiella Pneumoniae Carbapenemase (KPC) infections: a review of published case series and case reports
-
The combination of decoy receptor 3 and soluble triggering receptor expressed on myeloid cells-1 for the diagnosis of nosocomial bacterial meningitis
Recent Blogs
Aims and scope
Annals of Clinical Microbiology and Antimicrobials considers good quality, novel and international articles of more than regional relevance; the journal covers the clinical microbiology of bacteria, viruses and fungi, as well as antimicrobial treatment of infectious diseases.
Research articles must include epidemiological and/or clinical information about isolates; we also welcome systemic reviews, and clinical case reports of high international significance.
We often invite reviews focussing on important current issues, and we also welcome submission of formal systematic reviews. Authors who are considering submit an unsolicited review should contact the editorial office for advice on the relevance of the content and the quality of evidence that is expected.
Editor profiles
Hakan Leblebicioglu, Editor-in-Chief
Professor Leblebicioglu is the former head of the Department of Infectious Diseases and Clinical Microbiology at Ondokuz Mayis University Medical School in Turkey and working at Samsun Liv Hospital, Turkey. He is currently a Fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), a founding member and Honorary Chief of ESCMID Study Group for Infections in Travelers and Migrants (ESGITM) and also a member of the Study Group for Viral Hepatitis (ESGVH). He has authored 162 publications in peer-reviewed international medical journals (H index is 31 in Web of Science), mainly in Crimean Congo hemorrhagic fever, viral hepatitis and healthcare associated infections. He has conducted workshops and courses in the area of effective communication, presentation skills, proposal and manuscript writing.
Tim McHugh, Editor-in-Chief
Professor McHugh leads the UCL Centre for Clinical Microbiology (CCM). Located at the Royal Free Hospital, CCM aims to improve the diagnosis and treatment of infectious diseases and contributes in the areas of antimicrobial resistance, infection in patients with immunosuppression and hospital acquired infection. Prof McHugh has a particular focus on respiratory infection and CCM has activities in all stages of the TB drug development pathway with projects on evaluation of new compounds as well as supporting the laboratory aspects of clinical trials. An underlying theme is the development of biomarkers of treatment outcome, whether transcriptomic analysis of in vitro treatments or the more complex picture of monitoring outcome in patients.
Annual Journal Metrics
-
Speed
92 days to first decision for reviewed manuscripts only
37 days to first decision for all manuscripts
131 days from submission to acceptance
13 days from acceptance to publicationCitation Impact
2.924 - 2-year Impact Factor
3.032 - 5-year Impact Factor
1.367 - Source Normalized Impact per Paper (SNIP)
1.060 - SCImago Journal Rank (SJR)Usage
356,195 Downloads
264 Altmetric Mentions
